Eli Lilly and Company discovers, develops, manufactures, and sells products in two business segments human pharmaceutical products and animal health products. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The Company�s products are Humulin, Jentadueto, Axiron, Cymbalta, Strattera, Amyvid, Gemzar, Erbitux, Effient, ReoPro, Posilac, Posilac and Surmax. Its products in Late-Stage are Dulaglutide, Empagliflozin, Ramucirumab, Evacetrapib, Necitumumab, Tanezumab, Edivoxetine, Liprotamase and Ramucirumab.